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Community engagement and integrated health and polio
immunisation campaigns in conflict-affected areas of
Pakistan: a cluster randomised controlled trial
Muhammad Atif Habib, Sajid Soofi, Simon Cousens, Saeed Anwar, Najib ul Haque, Imran Ahmed, Noshad Ali, Rehman Tahir, Zulfiqar A Bhutta

Summary

Background Pakistan faces huge challenges in eradicating polio due to widespread poliovirus transmission and
security challenges. Innovative interventions are urgently needed to strengthen community buy-in, to increase the
coverage of oral polio vaccine (OPV) and other routine immunisations, and to enhance immunity through the
introduction of inactivated polio vaccine (IPV) in combination with OPV. We aimed to evaluate the acceptability and
effect on immunisation coverage of an integrated strategy for community engagement and maternal and child health
immunisation campaigns in insecure and conflict-affected polio-endemic districts of Pakistan.
Methods We did a community-based three-arm cluster randomised trial in healthy children aged 1 month to 5 years
that resided within the study sites in three districts of Pakistan at high risk of polio. Clusters were randomly assigned
by a computer algorithm using restricted randomisation in blocks of 20 by an external statistician (1:1:1) to receive
routine polio programme activities (control, arm A), additional interventions with community outreach and
mobilisation using an enhanced communication package and provision of short-term preventive maternal and child
health services and routine immunisation (health camps), including OPV (arm B), or all interventions of arm B with
additional provision of IPV delivered at the maternal and child health camps (arm C). An independent team conducted
surveys at baseline, endline, and after each round of supplementary immunisation activity for acceptability and effect.
The primary outcome measures for the study were coverage of OPV, IPV, and routine extended programme on
immunisation vaccines and changes in the proportion of unvaccinated and fully vaccinated children. This trial is
registered with ClinicalTrials.gov, number NCT01908114.
Findings Between June 4, 2013, and May 31, 2014, 387 clusters were randomised (131 to arm A, 127 to arm B, and 129
to arm C). At baseline, 28 760 children younger than 5 years were recorded in arm A, 30 098 in arm B, and 29 126 in
arm C. 359 clusters remained in the trial until the end (116 in arm A, 120 in arm B, and 123 in arm C; with 23 334 children
younger than 5 years in arm A, 26 110 in arm B, and 25 745 in arm C). The estimated OPV coverage was 75% in arm A
compared with 82% in arm B (difference vs arm A 6·6%; 95% CI 4·8–8·3) and 84% in arm C (8·5%, 6·8–10·1; overall
p<0·0001). The mean proportion of routine vaccine doses received by children younger than 24 months of age was
43% in arm A, 52% in arm B (9%, 7–11) and 54% in arm C (11%, 9–13; overall p<0·0001). No serious adverse events
requiring hospitalisation were reported after immunisation.
Interpretation Despite the challenges associated with the polio end-game in high-risk, conflict-affected areas of
Pakistan, a strategy of community mobilisation and targeted community-based health and immunisation camps
during polio immunisation campaigns was successful in increasing vaccine coverage, including polio vaccine coverage.
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Introduction
Pakistan, Afghanistan, and Nigeria are the only three
remaining countries with endemic polio.1 Although the
number of polio cases and their geographical spread
have reduced, insecurity, poor access to populations, and
residual pockets of circulating poliovirus in these three
countries remain an important challenge for global polio
eradication. Most routine childhood immunisations in
Pakistan are delivered at fixed immunisation sites, with
some outreach services through vaccinators; however,
coverage rates for many routine childhood immunisation
vaccines remain low, on average between 65% and
www.thelancet.com/lancetgh Vol 5 June 2017

73% for vaccines containing diphtheria, tetanus, and
pertussis (DTP).2 Oral polio vaccine (OPV) is delivered
differently. Although routine childhood immunisation
services should provide four doses of OPV (at birth, 6, 10,
and 14 weeks of age), repeated, concerted door-to-door
immunisation campaigns, called supplementary immun
isation activities, have been used to try to increase OPV
coverage.3 The supplementary immunisation activities
are household-level campaigns organised by the Pakistan
national polio programme and usually last 5 days (3 days
to visit all households, with 2 days for return visits to
households with initially absent or missed children with
e593
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Research in context
Evidence before this study
We did a systematic review of available information about
strategies for addressing polio eradication in conflict and
insecurity settings using the broad terms “polio” and
“vaccination strategies”, and MeSH terms “insecurity”, “war”,
and “conflict”. The search encompassed Jan 1, 2000, to Dec
31, 2016, and was not restricted to the English language. Our
review did not identify any randomised controlled trials or
systematic reviews of immunisation strategies addressing polio
programme refusals or insecurity. We assessed a large number of
reports documenting the temporal association between conflict,
insecurity, and risks to polio eradication, as well as re-emergence
of polio. These issues have been compounded in the past
5–6 years by attacks on polio and health workers and insecurity
had been documented as an important barrier to polio
eradication activities in conflict settings. In other instances,
negative propaganda by some religious factions and
obscurantists have affected population uptake of oral polio
vaccine (OPV) and led to refusals. Although a combination of
approaches has been suggested to circumvent these issues, the
scientific basis for community-based approaches in such
settings is very limited. A Cochrane review of strategies to scale
up childhood immunisations also did not present any
information from studies done in such conflict settings or
insecure contexts. Barring one report of mass immunisation in
northern Nigeria and other approaches using the military in
Angola, we identified no reports of evaluations of strategies to
scale up polio or routine immunisations in conflict settings. A
systematic review of service delivery platforms for maternal,
newborn, and child health strategies in Pakistan did not identify
a study of routine immunisations or polio-associated
interventions.

See Online for appendix
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door-to-door OPV administration to children younger
than 5 years of age by health workers. These children
have their fingers marked using permanent ink for ease
of identification in post-vaccination mop-up activities
and surveys. Supplementary immunisation activities
have been particularly challenging in parts of the country
affected by insurgency and insecurity, with groups
such as the Taliban limiting access to populations,4
disinformation leading to refusal of OPV,5 and attacks
targeting polio workers.6 In particular, in the high-risk
areas of northwest Pakistan and several slums of Karachi,
polio workers have been subjected to several attacks and
assassinations, with bans imposed on polio vaccination
activities by the Pakistani Taliban and other extremist
groups, as well as general insecurity impeding the access
of polio programme teams to such communities.7
These barriers to the polio programme activities are
compounded by inefficiencies within the routine child
hood immunisation programme, the poor state of
environmental sanitation, and high burdens of childhood
diarrhoea and malnutrition, which make transmission

Added value of this study
To our knowledge, our study is the first scientifically designed
formal evaluation of a community-based strategy to approach
high-risk populations in conflict-affected and insecure
populations with an integrated package of maternal and child
health and immunisation services delivered during routine
polio campaigns. The results indicated widespread acceptance,
with more than two-thirds of target children and families in
these districts accessing these short-term fixed camps during
the 4 days of the campaigns. Contrary to initial fears, the
coverage of OPV increased 8·5% overall, uptake of inactivated
polio vaccine administered alongside OPV was high, and the
number of children who were not immunised was reduced
overall.
Implications of all the available evidence
Our findings strongly support the adaptation of comparable
community-based integrated strategies for community
engagement, grass-root mobilisation, and integration of
polio, routine immunisation, and maternal and child health
services in the residual high-risk population reservoirs with
circulating poliovirus in Pakistan and the conflict-affected
bordering areas with Afghanistan. These strategies can be
integrated with routine health and immunisation services.
Our findings suggest that engaging local community
members and political leaders is important to secure access
and community buy-in. A historical review of the political
determinants of polio in five countries affected by Islamist
militancy also concluded that rather than military victory
against the militants, securing local de-facto political support
was crucial for success.

more probable and potentially impair the response to
OPV.8–10 An important issue in many areas is insufficient
community buy-in for the polio-focused supplementary
immunisation activities and general fatigue with the
repeated rounds of house
hold OPV administration
(estimated to have exceeded 150 rounds to date).
These issues were brought to the fore by a massive
upsurge in polio cases in Pakistan (rising from 58 cases
in 2012, to 93 cases in 2013, and to 306 cases in 2014;
appendix). Additionally, the country faced the challenge
of introducing the inactivated polio vaccine (IPV) with
the third dose of DTP vaccine (DTP3), as recommended
by the WHO Strategic Advisory Group of Experts (SAGE)
committee for vaccines.11 The recommendation seeks to
address the risk of emergence of circulating vaccinederived polioviruses (cVDPV), typically cVDPV2, OPV
virus type 2, and the coordinated withdrawal of trivalent
OPV and its replacement by bivalent OPV.12 This
recommendation to introduce IPV was based on evidence
from studies documenting enhanced serum antibody
response and improved mucosal immunity with a
www.thelancet.com/lancetgh Vol 5 June 2017
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combination of OPV and IPV compared with OPV alone,
resulting in a substantial reduction in poliovirus
excretion,13–15 and protecting the population ahead of the
withdrawal of trivalent OPV vaccine. The bivalent OPV
was introduced in Pakistan in April, 2016.
Given the limited vaccine coverage of the routine
childhood immunisation programme, the context of
insecurity, and limited community engagement in some
populations, introduction of IPV into the national polio
eradication strategies in Pakistan posed numerous
challenges. In addition to the obvious questions around
the probable IPV coverage rates in view of low coverage
rates of routine childhood immunisation vaccines,
especially DTP3, key concerns were raised about the
possible negative consequences of IPV introduction
for the acceptance and coverage of the existing OPV pro
gramme, especially in areas where refusals of OPV were
noted within supplementary immunisation activities.
We hypothesised that in these insecure polio-endemic
areas of Pakistan with poorly functioning routine
childhood immunisation systems, a strategy of enhanced
community engagement together with the provision of
some maternal, child health, and immunisation services
Country boundary
Province boundary
District boundary
Study area

in time-limited camps alongside planned supplementary
immunisation activities would enhance overall OPV
coverage. We also hypothesised that this might be a useful
mechanism for introducing IPV and enhancing its
acceptability in such populations. We aimed to evaluate
the effect on vaccine coverage of this enhanced maternal,
child health, and immunisation service package, with or
without additional IPV, delivered through health camps
alongside the regular polio supplementary immunisation
activities.

Methods

Study design and participants
We did this community-based, three-arm cluster
randomised trial in three geographical areas in Pakistan
reported as high risk for polio by WHO (figure 1). These
areas were also selected for risks of ongoing insurgency
(Bajaur and Karachi) and general insecurity (Kashmore).
Healthy children aged 1 month to 5 years who lived within
the study sites, and who did not plan to travel away during
entire the study period, were eligible for the study.
Children with known thrombocytopenia or bleeding
disorders, who were acutely ill or with signs of acute

Gilgit
Khyber Pathtunkhwa

Bajaur
Tehsil Khar
Tehsil Mamund
Tehsil Salarzai
Tehsil Utmankhel
Tehsil Barang
Tehsil Nawagai

Azad Jammu and Kashmir
FATA

Punjab

Balochistan

Kashmore
Union council Kashmore 1 and 2
Union council Kandhkot 2, 3, and 4
Union council Malir
Union council Gulwali
Union council Dolatpur

Sindh

Karachi
Gadap Town
Union council 5-Songal
Union council 8-Manghopir

Gulshan Town
Union council 10-Pehelwan Goth
Union council 13-Safoorah Goth

Figure 1: Map of Pakistan showing study areas
FATA=Federally Administered Tribal Areas. KPK=Khyber Pakhtunkhwa. AJK=Azad Jammu and Kashmir.

www.thelancet.com/lancetgh Vol 5 June 2017

e595

Articles

387 clusters randomised

129 clusters
21 324 households visited
1193 locked
348 refused
19 783 completed
29 126 children <5 years

122 clusters
3060 households visited
2756 households surveyed
4182 children assessed

122 clusters
3059 households visited
2713 households surveyed
4031 children assessed

121 clusters
3630 households visited
2840 households surveyed
3123 children assessed

122 clusters
3660 households visited
2971 households surveyed
2999 children assessed

122 clusters
3637 households visited
2936 households surveyed
2969 children assessed

120 clusters
3600 households visited
3147 households surveyed
4136 children assessed

122 clusters
3660 households visited
3287 households surveyed
4286 children assessed

122 clusters
3627 households visited
3138 households surveyed
4208 children assessed

115 clusters
3450 households visited
2847 households surveyed
3177 children assessed

122 clusters
3660 households visited
3083 households surveyed
3324 children assessed

122 clusters
3632 households visited
2935 households surveyed
3361 children assessed

Endline

Round 1

123 clusters
3060 households visited
2445 households surveyed
3926 children assessed

Round 2

127 clusters
21 348 households visited
1030 locked
315 refused
20 003 completed
30 098 children <5 years

Community mobilisation
and health camps, and IPV (arm C)

Round 3

131 clusters
21 242 households visited
1305 locked
429 refused
19 508 completed
28 760 children <5 years

Community mobilisation
and health camps (arm B)

Round 4

Baseline

Control (arm A)

116 clusters
17 500 households visited
2016 locked
293 refused
15 191 completed
23 334 children <5 years

120 clusters
190 974 households visited
2015 locked
330 refused
17 629 completed
26 110 children <5 years

123 clusters
20 093 households visited
2255 locked
3238 refused
17 600 completed
25 745 children <5 years

Figure 2: Trial profile

infection (eg, fever ≥38 °C) at the time of supplementary
immunisation activity, or who had a diagnosis or
suspicion of immunodeficiency disorder were not eligible.
We did a baseline census in the three study areas to
collect demographic, socioeconomic, routine immun
isation, and health-seeking data. The baseline census was
done by locally recruited and trained data collection
teams, strictly independent of the implementing teams,
for 3 months. A structured questionnaire was developed
for the purpose and was pretested on 50 households from
a locality not included in the trial but having similar
sociodemographic conditions (appendix). Double data
entry and cleaning were done concurrently.
The ethics review committee of Aga Khan University
and the National Bioethics Committee granted approval
of the trial. In view of the importance of introduction of
IPV through the existing immunisation programme
without posing any risks to the existing OPV delivery
e596

strategy, we devoted considerable time to achieving
consensus among all national and provincial stakeholders.
During the inception phase, between October, 2012, and
June, 2013, a series of consultative meetings at provincial,
national, and international levels were held, resulting in
formal approval by the authorities. Life and injury
insurance for all participants and staff involved in the trial
and institutional indemnification were also provided;
because no insurance company in Pakistan was prepared
to provide this cover, it was secured from an overseas
insurance company (Aon Insurance Managers,
Singapore). Individual level consent was taken from the
parent of the participating child.

Randomisation and masking
A computer algorithm was used to perform restricted
randomisation in blocks of 20 by matching the population
size, socioeconomic status, OPV coverage, and extended
programme on immunisation (EPI) coverage, to assign
(1:1:1) eligible clusters to three groups. An individual
cluster was defined as the area assigned to a team for
polio vaccination during supplementary immunisation
activities. Arm A (control) received the routine
im
mu
ni
sation package and additional OPV in
supplementary immunisation activities (no special
measures such as short message service messages,
posters, banners, or mass media promotions were
employed in these areas). Arm B received additional
interventions with community outreach and mobilisation
using an enhanced com
munication package, and
provision of maternal and child health immunisation
services through low-cost health camps established to run
from day 4 of polio supplementary immunisation
activities. The clusters in arm C received the same
intervention package as arm B with the addition of IPV
(Imovax, Sanofi Pasteur, Lyon, France) delivered at the
maternal and child health immunisation strategy camps.
The trial was designed to cover four consecutive
supplementary immunisation activity rounds over
12 months, with IPV administered in rounds one and
three, while the community mobilisation activities
continued throughout the duration of the project. An
independent team conducted baseline, end line and postsupplementation immunisation strategy surveys at the
end of each round (appendix). Because of the nature of
the intervention, trial investigators were not masked. The
main trial statistician (SC) was not involved in field
implementation.

Procedures
A community mobilisation plan and information,
education, and communication (IEC) materials—
specifically a pictorial booklet and counselling cards—
were prepared during the inception phase and ratified by
all relevant stakeholders. The IEC materials contained
information on maternal health, nutrition, hygiene and
sanitation, immunisation, polio, and health camps.
www.thelancet.com/lancetgh Vol 5 June 2017
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Teams of two female and one male community mobilisers
were recruited and trained to deliver the information
contained in the IEC material and were provided with an
IEC booklet and counselling cards as job aids. Each team
covered four clusters and delivered these key messages
through individual sessions with parents and group
sessions with male groups, female groups, and healthcare providers at cluster level. Sessions with community
and religious leaders, teachers, and other prominent
persons were done at union council level. Typically ten to
20 people attended the male and female group sessions;
five to ten attended the others. The sessions with healthcare providers and influencers were limited to the
introduction of the project, with a focus on the
importance of routine immunisation and OPV
administration (and IPV use as relevant to the specific
clusters). We also provided information regarding
maternal health, nutrition, hygiene and sanitation,
immunisation, and polio during sessions with female
members of the community. Although the study team
did not make direct contact with local militant leaders
and Taliban commanders, community elders were
closely consulted who might have communicated with
such individuals.
The community mobilisation teams also promoted
health camps offering maternal and child health
immunisation services during the scheduled supplemen
tation immunisation strategies, including missed OPV
doses. Promotion was limited to provision of information
regarding services being offered at health camps and
encouraging use of those services Additional information
about the availability of IPV for coadministration with
OPV (as needed) in the health camps was only provided
in clusters of arm C. This strategy was agreed with the
national polio programme to prevent any disinformation
about the existing OPV strategy. Based on instructions
from the health department, no large-scale public
dissemination was undertaken regarding IPV use and
availability. To avoid potential contamination between
arms, the community mobilisation teams informing
communities in arms B and C about health camps also
provided colour-coded invitation cards required for
visiting the health camps, and vaccine allocation
(additional IPV) was made as per the colour codes.
Details of community mobilisation sessions conducted
across sites and arms are in the appendix.
During each of the four supplementary immunisation
activity rounds, approximately 60 maternal and child
health and immunisation camps were held in clusters
of arms B and C. The camps generally started on the
fourth day of supplementary immunisation activities,
lasted for 3–4 days, and covered two adjacent clusters.
They were open for 7–8 h per day. In addition to the
fixed main camps, a few mobile camps were also
organised in some remote clusters to improve
community access as needed. Each health camp was
staffed by one supervising medical officer,
www.thelancet.com/lancetgh Vol 5 June 2017

one vaccinator, one paramedic, and two facilitators.
Staff provided counselling on hygiene, nutrition, and
routine immunisations and undertook general
maternal and child health assessments. The health
camp staff were trained to provide standard medical
care, follow good clinical practices, maintain a strict
cold chain, and follow safe injection practices. The
health-care providers in the camps delivered nutrition
interventions such as micronutrient supplements,
routine immunisations, and OPV as needed. Written
consent was obtained for IPV administration because it
was not included in routine immunisation vaccines at
that time. Primary care medications for common
illnesses were admin
istered as per WHO and
Control (arm A;
n=28 760)

Community mobilisation Community mobilisation
and health camps (arm B; and health camps with IPV
n=30 098)
(arm C; n=29 126)

Children <5 years old
Karachi

7415 (26%)

7579 (25%)

7310 (25%)

11 705 (41%)

12 481 (41%)

11 995 (41%)

9640 (34%)

10 038 (33%)

9821 (34%)

Female

13 787 (48%)

14 341 (48%)

13 926 (48%)

Male

14 973 (52%)

15 757 (52%)

15 200 (52%)
2052 (7%)

Bajaur
Kashmore
Sex

Age (months)
0–5

2032 (7%)

2113 (7%)

6–11

2493 (9%)

2493 (8%)

2474 (8%)

12–23

4646 (16%)

4907 (16%)

4761 (16%)

24–59

19 589 (68%)

20 585 (68%)

19 839 (68%)

Access to improved water source*
No

3517 (12%)

5339 (18%)

4398 (15%)

Yes

25 243 (88%)

24 759 (82%)

24 728 (85%)

Access to a latrine
No

7114 (25%)

6946 (23%)

7123 (24%)

Yes

21 646 (75%)

23 152 (77%)

22 003 (76%)

Vaccination card available
No

25 050 (87%)

26 024 (86%)

25 209 (87%)

Yes

3710 (13%)

4074 (14%)

3917 (13%)

Immunisation status†
Full

6280 (22%)

6499 (22%)

6379 (22%)

Partial

10 259 (36%)

10 916 (36%)

10 566 (36%)

No routine EPI

12 221 (42%)

12 683 (42%)

12 191 (42%)

Received OPV during last campaign
No

5540 (19%)

5656 (19%)

5408 (19%)

Yes

23 220 (81%)

24 442 (81%)

23 718 (81%)

Received vitamin A during last campaign‡
No

5156 (19%)

5342 (19%)

3767 (14%)

Yes

21 572 (81%)

22 643 (81%)

23 307 (86%)

IPV=inactivated polio vaccine. EPI=expanded programme on immunisation. OPV=oral polio vaccine. *Improved source
includes government tap, well, or hand pump; bottled water or mineral water; own tap, well, or hand pump; and
borehole. †Fully immunised defined as child has received all routine immunisation antigens for his age; partially
immunised defined as the child is not fully immunised; and no routine immunisation defined as the child did not
receive any routine immunisation antigen. ‡Of children aged 6 months or older at baseline.

Table 1: Baseline sociodemographic characteristics and immunisation status of children younger than
5 years and their families
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Karachi
Community
mobilisation
and health
camps
(arm B)
Children at
baseline

Bajaur
Community
mobilisation
and health
camps and
IPV (arm C)

Kashmore
Community
mobilisation
and health
camps and
IPV (arm C)

Community
mobilisation
and health
camps
(arm B)

Community
mobilisation
and health
camps and
IPV (arm C)

Community
mobilisation
and health
camps
(arm B)

12 481

11 995

10 038

9821

260

7579

7310

1

51

46

153

287

232

2

91

91

229

245

220

238

3

89

46

263

255

238

258

94

29

265

274

250

206

325

212

910

1061

940

962

BCG

4
Total
OPV
1

458

367

816

1087

1224

1155

2

674

358

977

902

1310

1449

3

625

335

939

1016

1327

1456

4

623

408

1112

1197

1257

1327

2380

1468

3844

4202

5118

5387

Total
Pentavalent
1

290

572

619

695

826

727

2

251

242

626

576

737

1138

3

227

248

646

754

912

1144

4

267

273

564

982

881

1124

1035

1335

2455

3007

3356

4133

Total
Measles
1

264

433

490

495

597

806

2

542

616

303

451

778

586

3

111

153

422

415

129

172

4

978

1040

325

356

447

320

1895

2242

1540

1717

1951

1884

1

NA

5851

NA

7431

NA

8469

2

NA

NA

NA

NA

NA

NA

3

NA

6344

NA

8318

NA

9102

Total
IPV

4

NA

NA

NA

NA

NA

NA

Total

NA

12 195

NA

15 749

NA

17 571

IPV=inactivated polio vaccine. OPV=oral polio vaccine. NA=not applicable.

Table 2: Numbers of vaccine doses delivered at health camps

Government of Pakistan guidelines.16 Children
receiving IPV were monitored for any adverse reaction
for 30 min after vaccination. Camp medical officers
provided a contact number for parents to call in the
event of any delayed adverse effect of IPV or other
injectable vaccines.
Based on the baseline census data, cluster-specific
vaccine record books were prepared. These books
contained details of children falling in the target age
range for vaccination and were used to record information
regarding vaccination at the health camps for these
children. Vaccination records for children who were born
after the census and were vaccinated at health camps
were also recorded in the vaccine record books.
e598

At every stage of the project, strict monitoring and
supervision was undertaken by both internal and external
monitors using checklists. Monitoring supervisors
conducted surprise visits to check the project activities
and refresher trainings were given to the community
mobilisation and health camp teams on the basis of their
recommendations.
We established five independent mobile data collection
teams of three people per union council or tehsil to do
surveys after the vaccination rounds on a subset of
households in each cluster to assess OPV and IPV
coverage. A list of 25–30 households was computergenerated by the data management unit for each cluster
from the existing sampling frame. Within a week of
completion of supplementary immunisation activities
and conclusion of camps in arms B and C, the data
collection teams visited the targeted clusters, identified
each household on the list, and, after verbal informed
consent, obtained information on OPV or IPV uptake
and source from the caregiver of the child.
After four supplementary immunisation activity
rounds, an end-line census was performed in all clusters
to assess the change in routine immunisation coverage,
OPV coverage, and the acceptability of IPV using the
same structured questionnaire as for the baseline survey
(appendix).

Outcomes
The primary outcome measures for the study were
coverage of OPV, IPV, and routine EPI vaccines and
changes in the proportion of unvaccinated and fully
vaccinated children between baseline and end-line
surveys. The original trial protocol also included a
primary endpoint of the prevalence of serum neutralising
antibodies to all three types of poliovirus in arm B versus
arm C, but the risks associated with blood sampling in
this region were considered too great to rely on this as a
main trial outcome. When registering the trial, we
therefore included this as a secondary endpoint, along
with estimation of stool shedding of poliovirus and
environmental sampling for poliovirus circulation. These
results will be reported separately.

Statistical analysis
We estimated that a sample size of 40 clusters per arm
per geographical study site with 150 children per cluster
would provide greater than 90% power to detect an
increase in OPV coverage from 80% to 95% in a given
site at the 5% level of significance and a coefficient of
variation of 0·14. Across the three sites, an overall
sample size of 120 clusters per arm with an average of
150 children per cluster, would provide 90% power to
detect an increase in OPV coverage from 80% to 85%.17
To estimate the sample size for the sequential surveys
of
coverage
estimates
after
supplementary
immunisation activity, a conservative OPV coverage of
80% with a 5% increase was assumed. A sample size of
www.thelancet.com/lancetgh Vol 5 June 2017
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Control (Arm A)

Community mobilisation and health
camps (arm B)

Community mobilisation and health
camps and IPV (arm C)

Estimated coverage

Estimated coverage Coverage difference
(95% CI)

Estimated coverage

p value*

Coverage difference
(95% CI)

Round 1
Karachi

63% (53 to 71)

81% (74 to 87)

18·6% (7·2 to 30·1)

75% (66 to 82)

12·3% (–0·2 to 24·9)

Bajaur

77% (74 to 80)

79% (77 to 82)

1·9% (–1·9 to 5·7)

81% (78 to 83)

3·5% (–0·4 to 7·4)

0·0072

Kashmore

72% (73 to 74)

76% (74 to 78)

3·7% (1·0 to 6·4)

78% (76 to 80)

5·4% (2·9 to 7·9)

0·0002

Total

71% (68 to 74)

78% (76 to 80)

6·6% (3·5 to 9·7)

78% (76 to 80)

6·6% (3·4 to 9·8)

<0·0001

Karachi

72% (65 to 79)

80% (74 to 84)

7·4% (–1·4 to 16·2)

84% (80 to 88)

12·0% (3·8 to 20·1)

0·0142

Bajaur

76% (73 to 78)

83% (80 to 85)

6·9% (3·4 to 10·1)

84% (81 to 86)

7·7% (4·3 to 11·2)

<0·0001

Kashmore

75% (72 to 77)

80% (77 to 82)

5·2% (2·2 to 7·0)

82% (78 to 84)

7·0 (3·5 to 10·4)

Total

75% (73 to 76)

81% (79 to 83)

6·2% (3·6 to 8·8)

83% (81 to 85)

8·4% (5·8 to 11·0)

0·21

Round 2

0·0001
<0·0001

Round 3
Karachi

77% (67 to 84)

82% (78 to 86)

5·5% (–4·0 to 14·9)

88% (84 to 90)

10·8% (1·9 to 19·8)

0·0167

Bajaur

77% (75 to 80)

86% (84 to 88)

8·3% (5·5 to 11·1)

87% (84 to 89)

9·2% (5·4 to 13·0)

<0·0001

Kashmore

79% (75 to 82)

82% (81 to 84)

3·6% (0·0 to 7·2)

85% (83 to 86)

5·8% (2·2 to 9·5)

0·0054

Total

78% (75 to 80)

83% (82 to 85)

5·3% (2·3 to 8·2)

86% (84 to 87)

7·9% (5·0 to 10·8)

<0·0001

Round 4
Karachi

73% (68 to 77)

82% (74 to 87)

8·6% (1·1 to 16·1)

86% (83 to 89)

13·1% (7·8 to 18·5)

<0·0001

Bajaur

81% (78 to 83)

88% (86 to 90)

6·9% (3·8 to 10·0)

90% (88 to 91)

8·6% (5·6 to 11·7)

<0·0001

Kashmore

76% (74 to 78)

86% (84 to 87)

9·5% (6·9 to 12·2)

87% (85 to 89)

11·1% (8·3 to 13·9)

<0·0001

Total

77% (75 to 79)

85% (83 to 87)

8·3% (6·0 to 10·6)

88% (86 to 89)

10·7% (8·7 to 12·6)

<0·0001

75% (74 to 77)

82% (81 to 83)

6·6% (4·8 to 8·3)

84% (83 to 85)

8·5% (6·8 to 10·1)

<0·0001

Overall (all sites, all rounds)

OPV=oral polio vaccine. *Testing the null hypothesis of no differences in coverage across the three arms. Numbers in parantheses are 95% CI.

Table 3: OPV coverage during each round of supplementary immunisation activities

3048 per site (rounded to 3050) was estimated,
assuming a design effect of 2, to provide 80% power at
the 5% level of significance with 5% attrition. The
estimate was revised to 3619 (rounded to 3600) after the
first round using 20% attrition to account for nonresponse.
All data were double-entered using Visual FoxPro and
backed up at the data management unit at Aga Khan
University, with hard copies archived and stored at the
institution’s data repository. Demographic, clinical, and
vaccination data were merged and analysed using Stata
(versions 12 and 14). We calculated area and round-specific
vaccination coverage for all arms across baseline, surveys
after supplementary immunisation activities, and end-line
surveys. We analysed vaccination coverage using a
generalised linear model with the binomial probability
model and identity link function to produce estimates of the
percentage point difference in coverage between arms. We
accounted for the clustered nature of the data using Taylorlinearised variance estimates with the three study areas
treated as strata and the randomised clusters as primary
sampling units. The number of doses administered was the
count of all doses of OPV, IPV, and EPI vaccines actually
given excluding unused doses and wastage.
This trial is registered with ClinicalTrials.gov, number
NCT01908114.
www.thelancet.com/lancetgh Vol 5 June 2017

Role of the funding source
The funders of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report. The corresponding author had full access to all
the data in the study and had final responsibility for the
decision to submit for publication.

Results
Between June 4, 2013, and May 31, 2014, 387 clusters were
randomised (131 to arm A, 127 to arm B, and 129 to
arm C). At baseline, 28 760 children younger than 5 years
were recorded in arm A, 30 098 in arm B, and 29 126 in
arm C. 359 clusters remained in the trial until the end
(116 in arm A, 120 in arm B, and 123 in arm C; with
23 334 children younger than 5 years in arm A, 26 110 in
arm B, and 25 745 in arm C; figure 2).
Baseline sociodemographic characteristics of enrolled
children and their families were similar (table 1) but with
slightly poorer access to an improved water source in
arm B. Few children (13%) had vaccination cards available
and 42% of children were reported to have received no
routine EPI vaccination at all. Most children (81%) were
reported to have received OPV during the last round of
supplementary immunisation activity and a similar
proportion was reported to have received vitamin A drops
during the preceding 6 months.
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Figure 3: OPV coverage by rounds
OPV=oral polio vaccine. IPV=inactivated polio vaccine.

The number of vaccine doses delivered at health camps
held during each of the four supplementary immunisation
activity rounds are shown in table 2. 23 343 children
received 53 359 doses of routine immunisations (includ
ing 22 399 OPV doses). 26 867 children younger than
5 years also received 45 515 doses of IPV at the maternal
and child health and immunisation camps. No health
camps were held in the control arm (arm A). No serious
adverse events requiring hospitalisation were reported
after immunisation. There were some events of fever and
pain at the site of injection that were treated either at
health camps or the study team.
Control (arm A)
Baseline

End line

Across all four rounds, the average estimated coverage
of OPV was 75% (95% CI 74–77) in arm A, 82% (81–83%)
in arm B, and 84% (95% CI 83–85%) in arm C
(overall p<0·0001; table 3). On average, across rounds,
coverage was 6·6 percentage points (95% CI 4·8–8·3)
higher in arm B than in arm A and 8·5 percentage points
(6·8–10·1) higher in arm C than in arm A. A consistent
pattern across sites and across rounds was observed of
higher coverage in the two intervention arms (B and C)
than in control arm (arm A; figure 3).
The proportion of unvaccinated children according to
the routine childhood immunisation schedule was 42%
in each arm at baseline (table 4). At end line, this
proportion was reduced to 36% (95% CI 32–41%) in
arm A, 28% (95% CI 24–31) in arm B, and 27% (24–31) in
arm C. Similarly the proportion of fully vaccinated
children was about 22% at baseline in all three arms. At
end line, this proportion had increased to 25% (22–28) in
arm A, 32% (29–35) in arm B, and 34% (31–37) in arm C.
A consistent pattern was seen across sites. The proportion
of fully vaccinated children increased in the
two intervention arms compared with the control arm
(7·3% [95% CI 4·5–10·0] increase in arm B vs arm A;
9·5% [6·9–12·0] increase in arm C vs arm A; overall
p<0·0001).
The mean proportion of routine childhood
immunisation doses that each child received was 39%
(36–42) in all three arms at baseline and increased to 43%
(40–45) in arm A, 52% (49–55) in arm B, and 54% (51–57)
in arm C at end line (table 5). The proportion of vaccine
doses received increased in all three sites. Children in
Karachi received, on average, a higher proportion of

Community mobilisation and health
camps (arm B)

Community mobilisation and health
camps and IPV (arm C)

Baseline

Baseline

End line

End line

Karachi
Not immunised

30% (24–36)

25% (21–29)

27% (22–34)

16% (12–21)

25% (21–31)

11% (9–13)

Partially immunised

29% (26–32)

26% (24–30)

29% (27–32)

30% (27–33)

33% (31–35)

34% (30–38)

Fully immunised

41% (36–46)

49% (44–53)

43% (37–49)

54% (48–60)

41% (37–46)

56% (51–61)
48% (46–50)

Bajaur
Not immunised

62% (59–66)

60% (57–62)

63% (59–67)

47% (45–49)

64% (61–68)

Partially immunised

23% (19–27)

22% (19–25)

23% (19–28)

27% (25–29)

21% (17–26)

25% (23–28)

Fully immunised

15% (14–16)

19% (17–20)

14% (13–16)

26% (24–28)

14% (13–16)

26% (25–28)

Kashmore
Not immunised

29% (23–35)

19% (14–25)

27% (22–34)

16% (12–21)

26% (21–33)

17% (13–21)

Partially immunised

56% (49–63)

64% (57–71)

58% (51–65)

62% (54–69)

57% (50–64)

56% (49–63)

Fully immunised

15% (12–20)

17% (13–21)

14% (11–19)

22% (17–27)

17% (13 –21)

27% (22–32)

All sites combined
Not immunised

42% (38–47)

36% (32–41)

42% (38–47)

28% (24–31)

42% (38–46)

27% (24–31)

Partially immunised

36% (32–40)

39% (34–45)

36% (32–41)

40% (36–45)

36% (32–40)

39% (35–43)

Fully immunised

22% (19–25)

25% (22–28)

22% (19–24)

32% (29–35)

22% (19–25)

34% (31–37)

EPI=expanded programme on immunisation. IPV=inactivated polio vaccine. Numbers in parantheses are 95% CI.

Table 4: Vaccination status of children according to routine EPI schedule

e600

www.thelancet.com/lancetgh Vol 5 June 2017

Articles

Control (arm A)
Baseline

End line

Community mobilisation and health camps (arm B)

Community mobilisation and health camps and IPV (arm C)

Baseline

Baseline

End line

End line

Karachi

59% (53 to 65; 7415)

60% (57 to 64; 5193)

61% (54 to 67; 7579)

70% (65 to 76; 7090)

61% (56 to 66; 7310)

74% (70 to 78; 6640)

Bajaur

28% (26 to 30; 11 705)

32% (30 to 33; 9069)

27% (25 to 29; 12 481)

42% (40 to 44; 9641)

26% (24 to 28; 11 995)

41% (40 to 43; 9576)

Kashmore

38% (34 to 42; 9640)

43% (40 to 47; 9072)

37% (33 to 41; 10 038)

52% (49 to 56; 9529)

39% (34 to 43; 9821)

52% (49 to 56; 9529)

All sites combined

39% (36 to 42; 28 760)

43% (40 to 45; 23 334)

39% (36 to 42; 30 098)

52% (49 to 55; 26 110)

39% (36 to 42; 29 126)

54% (51 to 57; 25 745)

Data are mean percentage (95% CI; n). EPI=expanded programme on immunisation. IPV=inactivated polio vaccine. *58% means that on average children had received 58% of their scheduled EPI vaccinations.

Table 5: Mean proportion* of scheduled EPI vaccine doses actually received, by study site and arm

vaccine doses than children in the other two sites. The
percentage point increase in the proportion of scheduled
vaccine doses received by the children versus the control
arm A, was estimated to be 9% (95% CI 7–11) for arm B
and 11% (9–13) for arm C (table 6).
The estimated coverage from post-vaccination surveys
of IPV in round 1 in arm C was 86·3% (95% CI
81·7–89·9) for Karachi, 90·0% (87·4–92·2) for Bajaur,
and 95·9% (93·6–97·3) for Kashmore. The estimated
coverage from post-vaccination surveys of IPV in round 3
in arm C was 93·2% (89·9–95·5) for Karachi, 86%
(82·6–88·6) for Bajaur, and 98·6% (97·3–99·3) for
Kashmore in round 3 (table 7). Coverage with IPV in
arm C was higher than that with OPV at both rounds
(1 and 3) at which it was administered (greater than 85%
at both rounds across all three areas; table 7).
Completeness of post-supplementary immunisation
surveys was consistently very high in Kashmore and,
with the exception of round 1 in control arm, in Bajaur as
well (appendix). Completeness in Karachi was
consistently lower than the other two sites but still
reasonably high with the exception of round 2. The low
coverage in survey completeness in round 1 of Bajaur
and round 2 of Karachi reflects problems of accessibility
due to the operations by security forces in some of the
areas.
Data for the reasons for non-receipt of OPV and IPV
were also collected during the surveys (appendix). For
OPV, the most common reasons for non-receipt were
that the team did not visit and the child was away at the
time of the supplementary immunisation activities and
this pattern was consistent across arms, rounds, and
sites. For IPV, the most common reason for non-receipt
was the child being away from the area; the proportion of
refusals across sites was much lower for IPV than for
OPV, with some safety concerns largely restricted to
Karachi (appendix).

Discussion
The results of our study showed that, despite insecurity
due to militancy, and hesitancy in receiving OPV doses at
home during supplementary immunisation activities,
an innovative approach of community mobilisation
combined with delivery of maternal and child health and
immunisation interventions through temporary health
www.thelancet.com/lancetgh Vol 5 June 2017

Control
(arm A)

Test of null
Community
Community
mobilisation and health hypothesis that
mobilisation and
neither intervention
health camps (arm B) camps and IPV (arm C)
has any effect

Karachi

0 (control)

13% (10–16)

17% (14–20)

p<0·0001

Bajaur

0 (control)

10% (8–12)

10% (9–12)

p<0·0001

Kashmore

0 (control)

5% (1–10)

9% (4–13)

p=0·0003

All sites combined

0 (control)

9% (7–11)

11% (9–13)

p<0·0001

Data are the difference in the proportion of EPI vaccine doses received in arms B and C compared with arm A. Numbers
in parantheses are 95% CI. EPI=extended programme on immunisation. IPV=inactivated polio vaccine.

Table 6: Effect of interventions on proportion of scheduled EPI vaccinations received among children
aged <24 months

Round 1

Round 3

Karachi

86·3% (81·7–89·9)

93·2% (89·9–95·5)

Bajaur

90·0% (87·4–92·2)

86·0% (82·6–88·8)

Kashmore

95·9% (93·6–97·3)

98·6% (97·3–99·3)

All sites combined

92·2% (90·6–93·6)

94·3% (93·0–95·3)

Data are estimated mean coverage (95% CI). IPV=inactivated polio vaccine.

Table 7: IPV coverage by site for arm C

camps during supplementary immunisation activities
was effective in increasing coverage of OPV and other
childhood vaccines in Pakistan. Furthermore, the high
coverage achieved with IPV in intervention arm C
suggested that the strategy of delivering IPV alongside
OPV and other vaccines through fixed health camps is
both feasible and acceptable. The interventions were
well accepted, with the health camps accessed by families
with more than 50 000 child visits. The strategy of
delivering IPV with maternal and child health and
immunisation services resulted in an estimated IPV
coverage of about 80% with an excellent safety profile.
Contrary to concerns expressed about the possible
negative effects of IPV availability and administration on
OPV acceptance and uptake, coverage of OPV was
8·5 percentage points higher in the intervention arm
that also delivered IPV than in the arm that only delivered
OPV. Given the challenges associated with the polio
programme in Pakistan, this increase in OPV coverage is
important in achieving the threshold needed for stopping
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poliovirus circulation. The proportion of fully vaccinated
children was also increased.
The success and coverage gains in our trial occurred
before the initiation of military operations against
the Taliban and other militant groups in Federally
Administered Tribal Areas (FATA) and inaccessible areas
of Karachi.18 The community participation and acceptance
of the intervention reflected the widespread unmet needs
for maternal and child health and immunisation services
in these areas. In fact, the community mobilisation and
advocacy strategies focused on promoting general
maternal and child health and immunisations without
the singular focus on polio vaccination. Our findings
support the hypothesis that the provision of polio
vaccines as part of a package of health services might be
a better way to engage local communities and religious
leaders than a polio-specific programme.19 Nigeria has
made good progress in reaching difficult populations
using a broadly comparable approach,20 although polio
has re-emerged after 2 years.21 Nevertheless, the situation
is much improved compared with a few years ago.
Our study had considerable challenges in execution.
First, at times due to the high demand for services at the
health camps, it was difficult for project staff to control
the crowds that turned out. To counter this, we used the
community leaders and local community volunteers for
support. Second, observation of vaccinators revealed
some errors in injection technique during the first
round—highlighting the need for appropriate training of
vaccinators and supervisors. Fortunately, this was not
associated with any serious adverse events but was a
major source of anxiety for national polio programme
managers and local political leadership in FATA where
some reports of adverse effects had affected a previous
measles vaccination campaign in Khyber Pakhtunkhwa.22
To minimise the risk of problems, we recruited
experienced vaccinators from the public sector and
provided 5 days of training on standard WHO methods
for vaccination. Third, maintenance of the vaccine cold
chain in camps was a challenge; to address this,
vaccination teams were given adequate volumes of ice
packs and back-up thermometers. The vaccines used in
the study had vaccine vial monitors and staff were trained
in their use. Finally, uniform access and coverage was a
challenge: 29 (16 in arm A, seven in arm B, and six in
arm C) of the 387 clusters became inaccessible at
different times throughout the course of the project due
to insecurity and imposition of local curfews. The study
was limited by the fact that coverage estimates were
largely based on family reports and the relatively lower
completeness of post-supplementary immunisation
activity surveys in Karachi.
As per the recommendation of the Global Polio
Eradication Initiative, IPV should now have been
introduced into the routine immunisation schedule of all
countries that were previously using OPV alone.23 This
decision is now beset with the challenges of a global IPV
e602

shortage and prioritisation of supply to some countries.24
Countries such as Pakistan, where the childhood routine
immunisation coverage is low among some high-risk
populations, need to identify strategies to maximise
coverage with OPV and IPV. Our experience indicates
that this can be done through short-term camps linked to
supplementary immunisation activities. However, this
provision comes at a higher cost and with additional
needs for human resources, training, and monitoring
than routine immunisation services require, and should
not be considered a substitute for such services.
Nevertheless, in conflict zones and areas with high levels
of insecurity where access might be an issue, this could
be a pragmatic approach for achieving rapid coverage of
routine immunisation and IPV, as has also been shown
in refugee populations at risk of outbreaks.25
Our study is the first randomised trial of a strategy to
reach at-risk populations in high-risk and insecure
populations in Karachi and the border areas of Pakistan
and Afghanistan. The findings are consonant with
previous approaches to reach similar populations in
other regions affected by conflict and insecurity.26,27
Our experience provides objective evidence that it is
possible to gain community trust and achieve gains in
immunisation and OPV and IPV coverage using an
integrated approach, and has implications for
geographies facing resistance and limited community
engagement. Polio eradication in Pakistan faces ongoing
challenges including insurgency, conflict, and security
issues, and mistrust of OPV and its campaigns. The
areas of ongoing poliovirus circulation of FATA, Quetta
block, and upper Sindh are well known. The military
operation by the Pakistan Army in the high insurgency
areas of FATA, such as North Waziristan, Khyber Agency,
and Tirah valley has opened the opportunity to reach
hitherto inaccessible populations.18 Efforts at polio
eradication in Pakistan have accelerated rapidly since our
study and our findings have been made available to
policymakers developing response strategies in high-risk
areas. The holistic approach of community mobilisation
and establishing regular health camps, focusing on
maternal and child health and immunisation services
has since been widely implemented in high-risk union
councils of Karachi, as well as Khyber Pakhtunkhwa and
FATA and is beginning to yield results.28,29 This approach
is now being expanded to high-risk areas in Baluchistan
with persistent poliovirus circulation. This experience
also has implications for addressing the challenges in the
three residual pockets of polio globally, which also
happen to be geographies affected by conflict and
insecurity.30,31
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